AriBio Announces Completion of Enrollment in Phase 2 Alzheimer’s Study with AR1001
18.6.2020 03:00:00 EEST | Business Wire | Press release
AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced today, June 17th 2020, the completion of enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients are enrolled in the study, and the company is expecting to announce the topline results by early 2021.
“The completion of enrollment is a significant milestone for AriBio, and the company is extremely thankful for the combined efforts of our researchers, partners and the patient community. Advancing safe, effective and meaningful therapies for this devastating disease is our top priority at AriBio, and we look forward to presenting this data in the future,” said James Rock, Senior Vice President of Clinical Operations.
“Patients participating in the study are showing extremely low drop-out rates despite the COVID-19 pandemic and the safety profile of the drug has been encouraging,” said Matthew Choung, Chairman and CEO.
AriBio is the first company from South Korea to fully enroll a Phase 2 study for Alzheimer’s disease in the United States. The company aims to initiate another Phase 2 study for Mixed Dementia in 2021.
About AR1001
AR1001 is a first in class oral therapy with novel polypharmacological mechanisms for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity. AR1001 also has demonstrated positive effects against amyloid plaques and tau proteins.
About AR1001-ADP2-US01
AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized and Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer's disease. The study aims to assess the safety and efficacy of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. Last patient visit is expected to occur by the end of 2020. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio Co., Ltd.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on neurodegenerative and infectious diseases. AR1003 is the lead candidate for sepsis and COVID-19, which is preparing to enter a Phase 1 study in the United States by early 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005630/en/
Contact information
Fred Kim
734-516-8732
fredkim@aribiousa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Indra Group Exceeds All Its Guidances in 2025 and Sets Even More Ambitious Guidances for 2026 Than Those Set Out in Its 'Leading the Future' Strategic Plan26.2.2026 00:08:00 EET | Press release
Indra Group (MAD:IDR): • The fourth-quarter order intake in 2025 totaled €8.329 billion, raising thefull-year backlog to €16.083 billion (122% more than in 2024). The Defence backlog stood at €11.336 billion, far exceeding the target of more than €10 billion set for 2026. • Revenues increased by 13% in 2025 with respect to 2024, with double-digit year-on-year rises in Defence, ATM and Mobility Revenues recorded a 28% year-on-year rise in the final quarter of the year • EBITDA and EBIT recorded respective 17% and 18% year-on-year increases, while Indra Group’s profitability improved by half a percentage point, with the EBIT margin standing at 9.5% in 2025. The EBIT margin in the fourth quarter stood at 10.8%. • The net result totaled €436 M, a figure 57% higher than in 2024, while the cashgeneration (FCF) stood at €364 in 2025, set against €328 M in 2024. • R&D and innovation investment reached €472 million in fiscal year 2025. • The company sets itself financial guidances for 2026 that
OLX Launches Agentic AI Products to Transform Property Search and Car Sales at CLAIM AI in Lisbon25.2.2026 16:33:00 EET | Press release
OLX Group, the largest and fastest growing platform for vertical transactions in Europe and South Africa, today unveiled two new Agentic AI-powered products at CLAIM AI, its invite-only Lisbon conference for marketplace innovators. Launching in key OLX markets, CompassGPT introduces a conversational assistant to real estate search, while AutoIQ provides dealers with automotive intelligence, powering dealership performance and providing smarter sales tools, making OLX the only classifieds platform with Agents supporting both the demand and supply sides of digital marketplaces. "At OLX, we are not waiting for the future of AI – we are creating it. Our AI-first infrastructure, built since 2018 and combined with our proprietary data loop, allows us to deliver industry-defining agentic AI solutions that generic models simply cannot match,” said Christian Gisy, CEO of OLX. “CompassGPT and AutoIQ demonstrate how we're turning vision into measurable value for real estate agents, dealers and bu
Andersen Global Broadens Capabilities in Canada with Addition of Law Firm Parlee McLaws25.2.2026 16:30:00 EET | Press release
Andersen Global expands its presence in Canada with the addition of collaborating firm Parlee McLaws LLP, adding complementary legal capabilities to its existing platform in the country. Founded in 1883, Parlee McLaws provides a broad range of legal services including corporate and commercial law, securities law, litigation, real estate, labor and employment, intellectual property, energy, insolvency, administrative law, and online brand protection. With offices in Edmonton and Calgary, the firm has built a reputation for delivering practical, client-focused solutions tailored to the needs of businesses and individuals across industries. “Our collaboration with Andersen Global provides our clients with access to a broader suite of global resources while maintaining the personalized service and deep regional knowledge that define our firm,” said Jerri L. Cairns, managing director of Parlee McLaws. “We look forward to working together to deliver integrated solutions that address the comp
Stonebranch Unveils Latest Release of Universal Data Mover Gateway (UDMG), Advancing Orchestrated B2B MFT25.2.2026 16:00:00 EET | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, today announced the latest release of its Universal Data Mover Gateway (UDMG) — an enterprise-grade managed file transfer (MFT) solution purpose-built for secure, orchestrated B2B data exchange across hybrid landscapes. “In today’s enterprises, file transfer is not a standalone task. It’s the backbone of data pipelines, analytics, and critical business processes,” said Giuseppe Damiani, CEO of Stonebranch. “By orchestrating MFT alongside workload and infrastructure automation, Stonebranch turns file movement into a governed, observable, SLA-driven part of end-to-end enterprise workflows.” Secure, Modern B2B Managed File Transfer UDMG is designed specifically for external B2B data exchanges — where stringent security, regulatory compliance, SLA reliability, and diverse partner protocols require a modern B2B MFT solution. Enterprises can securely exchange data with partners, vendors, and customers worldwid
Axinn Adds Three Seasoned Antitrust Litigators, Reinforcing Trial Bench and West Coast Presence25.2.2026 16:00:00 EET | Press release
Axinn, Veltrop & Harkrider LLP announced today that Daniel Matheson, Katrina Rouse, and Jimmy Moore have joined its Antitrust practice as partners. Matheson arrives from the Federal Trade Commission (FTC), while Rouse and Moore join from the U.S. Department of Justice (DOJ) Antitrust Division. Rouse will join Axinn’s San Francisco office; Matheson and Moore will join the firm’s Washington, DC office. The additions strengthen Axinn's trial bench and West Coast practice as the firm continues to attract top antitrust talent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225403123/en/ Daniel Matheson (Left), Katrina Rouse (Center), and Jimmy Moore (Right) have joined Axinn, Veltrop & Harkrider's LLP Antitrust practice as partners. “Axinn continues to invest in top-tier talent and trial capabilities as we deepen our commitment to clients and their most complex challenges,” said Jeny Maier, managing partner of Axinn. “The addi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom